Royalty Pharma (RPRX) Income from Non-Controlling Interests (2019 - 2026)

Royalty Pharma has reported Income from Non-Controlling Interests for 8 years, with the latest figure at $173.6 million in Q1 2026.

• Quarterly Income from Non-Controlling Interests fell 11.03% year-over-year to $173.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $491.0 million (down 27.37% YoY) and the FY2025 annual result came in at $553.2 million, up 17.26% from the prior year.
• Income from Non-Controlling Interests grew to $173.6 million in Q1 2026 per RPRX's latest filing, from $141.7 million in the prior quarter.
• Over five years, Income from Non-Controlling Interests peaked at $262.4 million in Q3 2024 and troughed at -$153.9 million in Q4 2022.
• A 5-year average of $112.4 million and a median of $126.1 million in 2024 frame the typical range for Income from Non-Controlling Interests.
• The sharpest annual moves came in 2022 and 2025: Income from Non-Controlling Interests slumped 436.37% in 2022, then surged 2255.39% in 2025.
• Over 5 years, Income from Non-Controlling Interests stood at -$153.9 million in 2022, then soared by 245.02% to $223.2 million in 2023, then tumbled by 43.5% to $126.1 million in 2024, then climbed by 12.34% to $141.7 million in 2025, then rose by 22.48% to $173.6 million in 2026.
• According to Business Quant data, Income from Non-Controlling Interests over the past three periods registered $173.6 million, $141.7 million, and $156.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.